ghk cu constipation GHK-CU GHK-Cu Research Peptide Australia |
Description
The second group (the WT group) was the negative control and comprised wild-type animals
Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study
1992;62:S11-17
This places it in the same category as many research peptides, available through certain channels but without official sanction for human use
